Back to Directory

Coiled Therapeutics

London
Founded 2020
Clinical-stage precision oncology developing first-in-class TACC3 inhibitor therapeutics

Coiled Therapeutics is a UK-listed, clinical-stage oncology company developing precision cancer therapeutics against structurally complex, previously undruggable targets.

Its lead candidate, AO-252, is a first-in-class, orally administered small molecule inhibitor of TACC3 currently in Phase I trials for advanced solid tumours including ovarian and endometrial cancer, alongside an early-stage siRNA programme targeting STAT-6 for immunology.

The company uses an AI-driven design platform to discover small molecules against complex oncogenic targets, serving patients with hard-to-treat cancers.

BiotechOncologyDrug Discovery
Small Molecule DrugsRNA Therapeutics

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Company News3 Aug 2026

Coiled Therapeutics Doses First Patient with Reformulated AO-252

Coiled Therapeutics has dosed the first patient with a new lipid-based softgel formulation of AO-252, its TACC3 inhibitor for advanced solid tumours, with no treatment-related adverse safety findings observed. The reformulation is designed to improve drug absorption ahead of planned dose-expansion cohorts in ovarian and prostate cancer, targeting up to 30 patients by Q4 2026.

Source: Coiled TherapeuticsRead source

Company Notes

Previously Known As
Roquefort Therapeutics